STRATA Skin Sciences, Inc. announced that on May 23, 2018, directors James Coyne, Frank McCaney, Jeffrey O'Donnell, Sr., David Stone, and Kathryn Swintek resigned their positions as Board members effective with the closing of the equity investment under the securities purchase agreements on May 29, 2018. On May 23, 2018, the full Board of Directors unanimously approved the appointment of Uri Geiger, David Gill, Nachum Shamir, Samuel Rubinstein, and Dolev Rafaeli as Board members to fill the vacancies created by the resignations effective on May 29, 2018. Continuing on as Board members are LuAnn Via and Samuel Navarro.

Mr. Geiger will serve as Chairman of the Board. Dr. Uri Geiger, age 50, will become Chairman of the Board of Directors of the company effective upon closing of the Transaction. Dr. Geiger has served as Managing Partner of Accelmed.

Dr. Dolev Rafaeli, age 54, was appointed the company's Interim Chief Executive Officer effective April 10, 2018 and will become the company's Chief Executive Officer effective upon closing of the transaction. Dr. Rafaeli has over 25 years of experience in the healthcare, medical device, consumer and industrial services fields. He served as a Member of the Board of Directors of the company that founded the XTRAC, PhotoMedex since 2011 and was its CEO from 2006 to 2017.

Under his management at PhotoMedex, he oversaw sales growth from $19 million to over $300 million, driven by increases in brand portfolio, distribution channels and M&A transactions. He was President and CEO of Radiancy, a subsidiary of PhotoMedex, from 2006 to 2017. David N. Gill, age 63, served as the President and Chief Financial Officer of EndoChoice, Inc. from April 2016 through the sale of the company in November 2016 and as Chief Financial Officer from August 2014 to April 2016.

Previously, he served as the Chief Financial Officer of INC Research from February 2011 to August 2013 after having served as a board member and its audit committee chairman from 2007 to 2010. Shmuel Rubinstein (known by his nickname-Milky) Rubinstein, age 78, has served for over 20 years as the Chief Executive Officer and General Manager of Taro Pharmaceuticals Industries, a NASDAQ traded dermatology company. Under his management, Taro grew to become a multinational company with over 1000 employees worldwide and turnover of close to $450 million.

Nachum (Homi) Shamir, age 64, has been the President and Chief Executive Officer of Luminex Corporation since October 2014. Mr. Shamir previously served, from 2006 to 2014, as President and CEO of Given Imaging, a developer, manufacturer, and marketer of diagnostic products for the visualization and detection of disorders of the gastrointestinal tract.